Sign In
Buy XERS
$5.89
-0.110 (-1.83%)
At Close: Jun 03, 2026
Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
09:10am, Thursday, 09'th May 2024
Xeris Biopharma (XERS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago.
Xeris Biopharma and Beta Bionics join forces to develop dual-hormone pump for diabetes
10:01am, Monday, 06'th May 2024
Xeris Biopharma Holdings (NASDAQ:XERS) and Beta Bionics have announced an exclusive worldwide collaboration and license agreement aimed at revolutionizing diabetes management. The partnership seeks to
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
07:00am, Monday, 06'th May 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
07:00am, Thursday, 02'nd May 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Wednesday, 03'rd Apr 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
07:00am, Tuesday, 02'nd Apr 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial
Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
01:28am, Saturday, 30'th Mar 2024
Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with
Xeris Biopharma secures $200M in capital in debt refinancing deal; sees big 4Q revenue jump
09:57am, Wednesday, 06'th Mar 2024
Xeris Biopharma Holdings (NASDAQ:XERS) has bolstered its financial position through the refinancing of its debt with Hayfin Capital Management LLP, securing substantial capital upfront while reducing
Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates
09:16am, Wednesday, 06'th Mar 2024
Xeris Biopharma (XERS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
07:02am, Wednesday, 06'th Mar 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
07:00am, Wednesday, 06'th Mar 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial
Why Xeris (XERS) Might Surprise This Earnings Season
10:46am, Tuesday, 05'th Mar 2024
Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
07:00am, Wednesday, 28'th Feb 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
07:00am, Monday, 05'th Feb 2024
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
09:47am, Thursday, 11'th Jan 2024
Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Diseas
